This handout is for axial spondyloarthritis. Your care team identified this based on: chronic inflammatory back pain (insidious onset <45 y, >3 months) (asas-eular 2022; asas ibp criteria sieper 2009).
Other reasons your team may use this plan: enthesitis (achilles/plantar fascia), dactylitis, or asymmetric lower-limb oligoarthritis (asas-eular 2022); acute anterior uveitis, psoriasis, or ibd with chronic back pain (asas-eular 2022; acr/saa/spartan 2019); hla-b27 positive with chronic back pain or family history of spa (asas classification criteria rudwaleit 2009).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| structured exercise & physiotherapy | — | n/a | lifelong, regular | ASAS-EULAR 2022 — patient education + regular exercise (home + supervised land/water physiotherapy) is the lifelong cornerstone; preserves mobility and function alongside any pharmacotherapy |
| naproxen | 500 mg | PO | BID | ASAS-EULAR 2022 — NSAID first-line; continuous max-tolerated dosing preferred over on-demand when disease active; assess GI/CV/renal risk and add gastroprotection as needed |
| celecoxib | 200 mg | PO | once daily–BID | ASAS-EULAR 2022 — COX-2 selective alternative when GI risk; ≥2 different NSAIDs over ≥4 weeks each before declaring NSAID failure |
Plan: axSpA treat-to-target ladder (exercise + NSAID cornerstone → bDMARD by EMM → JAKi → switch)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Lifelong rheumatology follow-up; ongoing exercise/physiotherapy; consider tapering (not abrupt stop) of bDMARD in sustained remission; smoking cessation (accelerates radiographic progression); spine/posture and fall-prevention counselling; uveitis return precautions; vaccination + cardiovascular + bone-health maintenance; hip arthroplasty/spinal osteotomy referral for advanced structural disease (ASAS-EULAR 2022; ACR/SAA/SPARTAN 2019)
Guideline: 2022/2023 ASAS-EULAR axSpA management recommendations + 2019 ACR/SAA/SPARTAN AS/nr-axSpA guideline + ASAS classification criteria